Oxford Biomedica plc provided revenue guidance for the year 2022. For the year, the company expects total revenues to be lower than in 2021 (but significantly ahead of 2020) due to a pause in vaccine manufacturing activity while discussions with AstraZeneca continue on a potential extension of the supply agreement.